These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3731920)

  • 21. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
    Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
    Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redesigning beta-lactams to combat resistance: summary and conclusions.
    Rossolini GM
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():30-3. PubMed ID: 17488374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
    Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
    J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
    Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro antibacterial activity of cefpirome: a new cephalosporin; results of a multicenter study].
    Soussy CJ; Chanal M; Derlot E; Goldstein F; Duval J
    Pathol Biol (Paris); 1994 Oct; 42(8):754-60. PubMed ID: 7724247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.
    Bergeron MG; Bernier M
    Infection; 1994; 22(4):299-305. PubMed ID: 8002094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group.
    Piérard D; Emmerechts K; Lauwers S
    J Antimicrob Chemother; 1998 Apr; 41(4):443-50. PubMed ID: 9598775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of antimicrobial activity of beta-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan.
    Ishii Y; Alba J; Kimura S; Shiroto K; Yamaguchi K
    Int J Antimicrob Agents; 2005 Apr; 25(4):296-301. PubMed ID: 15784308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
    Ritchie DJ; Hopefl AW; Milligan TW; Byrne JE; Maddux MS
    Clin Ther; 1993; 15(1):107-13. PubMed ID: 8458040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.
    Watanabe A; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Tokue Y; Nukiwa T
    Chemotherapy; 2000; 46(3):184-7. PubMed ID: 10765033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefpirome susceptibility in staphylococci isolates.
    Poiată A; Tuchiluş C; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(1):276-9. PubMed ID: 17595881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.